AgomAb Director David Epstein Acquires 10,000 Shares in Two-Day Open Market Buys

Director David R. Epstein bought 5,000 shares twice in AgomAb Therapeutics (AGMB).

Across three purchases, AgomAb Therapeutics (AGMB) CFO buys 10,000 shares.

At $8.48 and $8.70 per share, AgomAb Therapeutics (AGMB) CEO buys shares in two purchases.

AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript

12 Health Care Stocks Moving In Thursday's After-Market Session

Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial

Why is Agomab Therapeutics stock sliding today?

Agomab stock jumps on positive trial data

12 Health Care Stocks Moving In Thursday's Intraday Session

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%

AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors